Targeted Therapy, Sorafenib, Shows Promise as First-Line Treatment for Previously Untreatable Rare Tumors
In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.